Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02309294 · ClinicalTrials.gov registry record · NA
14-Day Cumulative Irritation Patch Test in Subjects With Normal Skin
A NA study, sponsored by Church & Dwight Company.
- Completed
- Registry status
- NA
- Development phase
- 43
- Enrollment target
NCT02309294: Completed NA study, sponsored by Church & Dwight Company.
NCT02309294 is a NA study that has completed, run by Church & Dwight Company. The registered enrollment target is 43 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02309294, a NA study, has completed, sponsored by Church & Dwight Company.
- COMPLETED
- Registry status
- NA
- Development phase
- 43 participants
- Enrollment target
Study Summary
The objective of this study is to determine the ability of the study material to cause irritation to the skin of humans under controlled patch test conditions. Substances that come into contact with human skin need to be evaluated for their propensity to irritate and/or sensitize. This testing is a modified primary irritancy patch test that can detect weak irritants that require multiple applications to cause a skin reaction.
Primary Outcome
Score of less than or equal to 1.2 on the Cumulative Irritation Test scale (0-5).
Interventions
- DEVICE Novel lubricant Miami w/ fragrance
- DEVICE Novel lubricant Miami no fragrance
- DEVICE KY Liquid lubricant
- DEVICE Astroglide Gel lubricant
- DEVICE Wet Platinum lubricant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2014-12 |
| Est. Completion | 2014-12 |
| Phase | NA |
What the finished NCT02309294 record still lists
NCT02309294 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 5 interventions - of which Novel lubricant Miami w/ fragrance is the first listed.
NCT02309294 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02309294 about?
NCT02309294 is a clinical study titled "14-Day Cumulative Irritation Patch Test in Subjects With Normal Skin". The objective of this study is to determine the ability of the study material to cause irritation to the skin of humans under controlled patch test conditions. Substances that come into contact with human skin need to be evaluated for their propensity to irritate and/or sensitize. This testing is a ...
What is the current status of trial NCT02309294?
This trial is currently completed. It is a NA study. The enrollment target is 43 participants. The study started on 2014-12. Estimated completion is 2014-12.
What interventions are being tested in trial NCT02309294?
The interventions under investigation include: Novel lubricant Miami w/ fragrance (DEVICE), Novel lubricant Miami no fragrance (DEVICE), KY Liquid lubricant (DEVICE), Astroglide Gel lubricant (DEVICE), Wet Platinum lubricant (DEVICE).
Who is sponsoring clinical trial NCT02309294?
This trial is sponsored by Church & Dwight Company, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02309294's enrollment target sits among peer trials
43 1435th of 2000 higher than 565 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia